To get a better understanding of the kinetics of the expression of CXCR1, CXCR2 and the CXCR1/2 ligands (including IL-8), blood samples of patients with breast cancer or sarcoma will be collected at different timepoints. We expect that with these…
ID
Source
Brief title
Condition
- Miscellaneous and site unspecified neoplasms benign
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Determine the CXCR1 and CXCR2 expression on immune cells of cancer patients
prior and after treatment with doxorubicin.
Secondary outcome
Assess the expression of CXCR1 and CXCR2 ligands in the serum of the same
patients.
Background summary
Earlier experiments in mice and ex vivo in human PBMCs showed that doxorubicin
can alter the expression of different chemokine receptors on the surface of
immune cells. Furthermore, literature indicates that these chemokine receptors
are involved in the migration of immune cells towards the tumor site. Since
doxorubicin is a standard treatment modality for breast cancer and sarcoma
patients, we would like to determine the effect of doxorubicin treatment on the
expression of chemokine receptors on the immune cells in these patients.
Study objective
To get a better understanding of the kinetics of the expression of CXCR1, CXCR2
and the CXCR1/2 ligands (including IL-8), blood samples of patients with breast
cancer or sarcoma will be collected at different timepoints. We expect that
with these clinical data we can better understand the effect of doxorubicin on
the immune system, with the ultimate aim to improve the anti-tumor effectivity
of (combination-) treatment with doxorubicin.
Study design
Observational study.
Study burden and risks
We expect the burden and risks associated with participation to be small. A
possible minimal risk is pain and hematoma during and/or after blood
collection.
Einthovenweg 20
Leiden 2333ZC
NL
Einthovenweg 20
Leiden 2333ZC
NL
Listed location countries
Age
Inclusion criteria
- Chemotherapy naïve breast cancer and/or sarcoma patients
- Receive doxorubicin as standard treatment of care
- Age > 18
- Male and female patients
- Ability to understand the study and give signed informed consent prior to
beginning of protocol specific procedures
Exclusion criteria
If any other treatment is administered earlier to treat the disease, we cannot
include the patient.
Design
Recruitment
metc-ldd@lumc.nl
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL79973.058.21 |